Global Plasma Albumin 麻豆原创 Research Report 2023

Publication ID:

PB504239980

Publication Date:

April 26, 2023

Pages:

103

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Albumin is a water-soluble globular protein produced in the liver. It accounts for 50% of blood plasma proteins. These play a vital role in regulating blood volume and act as transporters for molecules such as few hormones, bile salts, and ions. Albumin is commonly used as blood volumizer in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries.
The global Plasma Albumin market was valued at US$ 5110 million in 2022 and is anticipated to reach US$ 8367.1 million by 2029, witnessing a CAGR of 7.3% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Plasma Albumin is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Plasma Albumin is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Plasma Albumin include Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrion, Shanghai RAAS and LFB Group, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Plasma Albumin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasma Albumin.
The Plasma Albumin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Plasma Albumin market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Plasma Albumin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Grifols
CSL
Takeda
Octapharma
CBPO
Hualan Bio
Kedrion
Shanghai RAAS
LFB Group
Biotest
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Segment by Type
20-25% Concentrations
5% Concentrations
Segment by Application
Therapeutics
Excipient
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Plasma Albumin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Plasma Albumin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Plasma Albumin 麻豆原创 Overview
1.1 Product Overview and Scope of Plasma Albumin
1.2 Plasma Albumin Segment by Type
1.2.1 Global Plasma Albumin 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 20-25% Concentrations
1.2.3 5% Concentrations
1.3 Plasma Albumin Segment by Application
1.3.1 Global Plasma Albumin 麻豆原创 Value by Application: (2023-2029)
1.3.2 Therapeutics
1.3.3 Excipient
1.3.4 Other
1.4 Global Plasma Albumin 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Plasma Albumin Revenue 2018-2029
1.4.2 Global Plasma Albumin Sales 2018-2029
1.4.3 Global Plasma Albumin 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Plasma Albumin 麻豆原创 Competition by Manufacturers
2.1 Global Plasma Albumin Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Plasma Albumin Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Plasma Albumin Average Price by Manufacturers (2018-2023)
2.4 Global Plasma Albumin Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Plasma Albumin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Plasma Albumin, Product Type & Application
2.7 Plasma Albumin 麻豆原创 Competitive Situation and Trends
2.7.1 Plasma Albumin 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Plasma Albumin Players 麻豆原创 Share by Revenue
2.7.3 Global Plasma Albumin 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Plasma Albumin Retrospective 麻豆原创 Scenario by Region
3.1 Global Plasma Albumin 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Plasma Albumin Global Plasma Albumin Sales by Region: 2018-2029
3.2.1 Global Plasma Albumin Sales by Region: 2018-2023
3.2.2 Global Plasma Albumin Sales by Region: 2024-2029
3.3 Global Plasma Albumin Global Plasma Albumin Revenue by Region: 2018-2029
3.3.1 Global Plasma Albumin Revenue by Region: 2018-2023
3.3.2 Global Plasma Albumin Revenue by Region: 2024-2029
3.4 North America Plasma Albumin 麻豆原创 Facts & Figures by Country
3.4.1 North America Plasma Albumin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Plasma Albumin Sales by Country (2018-2029)
3.4.3 North America Plasma Albumin Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Plasma Albumin 麻豆原创 Facts & Figures by Country
3.5.1 Europe Plasma Albumin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Plasma Albumin Sales by Country (2018-2029)
3.5.3 Europe Plasma Albumin Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Plasma Albumin 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Plasma Albumin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Plasma Albumin Sales by Country (2018-2029)
3.6.3 Asia Pacific Plasma Albumin Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Plasma Albumin 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Plasma Albumin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Plasma Albumin Sales by Country (2018-2029)
3.7.3 Latin America Plasma Albumin Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Plasma Albumin 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Plasma Albumin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Plasma Albumin Sales by Country (2018-2029)
3.8.3 Middle East and Africa Plasma Albumin Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Plasma Albumin Sales by Type (2018-2029)
4.1.1 Global Plasma Albumin Sales by Type (2018-2023)
4.1.2 Global Plasma Albumin Sales by Type (2024-2029)
4.1.3 Global Plasma Albumin Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Plasma Albumin Revenue by Type (2018-2029)
4.2.1 Global Plasma Albumin Revenue by Type (2018-2023)
4.2.2 Global Plasma Albumin Revenue by Type (2024-2029)
4.2.3 Global Plasma Albumin Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Plasma Albumin Price by Type (2018-2029)
5 Segment by Application
5.1 Global Plasma Albumin Sales by Application (2018-2029)
5.1.1 Global Plasma Albumin Sales by Application (2018-2023)
5.1.2 Global Plasma Albumin Sales by Application (2024-2029)
5.1.3 Global Plasma Albumin Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Plasma Albumin Revenue by Application (2018-2029)
5.2.1 Global Plasma Albumin Revenue by Application (2018-2023)
5.2.2 Global Plasma Albumin Revenue by Application (2024-2029)
5.2.3 Global Plasma Albumin Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Plasma Albumin Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Grifols
6.1.1 Grifols Corporation Information
6.1.2 Grifols Description and Business Overview
6.1.3 Grifols Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Grifols Plasma Albumin Product Portfolio
6.1.5 Grifols Recent Developments/Updates
6.2 CSL
6.2.1 CSL Corporation Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.2.4 CSL Plasma Albumin Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 Takeda
6.3.1 Takeda Corporation Information
6.3.2 Takeda Description and Business Overview
6.3.3 Takeda Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Takeda Plasma Albumin Product Portfolio
6.3.5 Takeda Recent Developments/Updates
6.4 Octapharma
6.4.1 Octapharma Corporation Information
6.4.2 Octapharma Description and Business Overview
6.4.3 Octapharma Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Octapharma Plasma Albumin Product Portfolio
6.4.5 Octapharma Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 CBPO Plasma Albumin Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Hualan Bio
6.6.1 Hualan Bio Corporation Information
6.6.2 Hualan Bio Description and Business Overview
6.6.3 Hualan Bio Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Hualan Bio Plasma Albumin Product Portfolio
6.6.5 Hualan Bio Recent Developments/Updates
6.7 Kedrion
6.6.1 Kedrion Corporation Information
6.6.2 Kedrion Description and Business Overview
6.6.3 Kedrion Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kedrion Plasma Albumin Product Portfolio
6.7.5 Kedrion Recent Developments/Updates
6.8 Shanghai RAAS
6.8.1 Shanghai RAAS Corporation Information
6.8.2 Shanghai RAAS Description and Business Overview
6.8.3 Shanghai RAAS Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Shanghai RAAS Plasma Albumin Product Portfolio
6.8.5 Shanghai RAAS Recent Developments/Updates
6.9 LFB Group
6.9.1 LFB Group Corporation Information
6.9.2 LFB Group Description and Business Overview
6.9.3 LFB Group Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.9.4 LFB Group Plasma Albumin Product Portfolio
6.9.5 LFB Group Recent Developments/Updates
6.10 Biotest
6.10.1 Biotest Corporation Information
6.10.2 Biotest Description and Business Overview
6.10.3 Biotest Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Biotest Plasma Albumin Product Portfolio
6.10.5 Biotest Recent Developments/Updates
6.11 Tiantan Bio
6.11.1 Tiantan Bio Corporation Information
6.11.2 Tiantan Bio Plasma Albumin Description and Business Overview
6.11.3 Tiantan Bio Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Tiantan Bio Plasma Albumin Product Portfolio
6.11.5 Tiantan Bio Recent Developments/Updates
6.12 Shuanglin Bio
6.12.1 Shuanglin Bio Corporation Information
6.12.2 Shuanglin Bio Plasma Albumin Description and Business Overview
6.12.3 Shuanglin Bio Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Shuanglin Bio Plasma Albumin Product Portfolio
6.12.5 Shuanglin Bio Recent Developments/Updates
6.13 Boya Bio
6.13.1 Boya Bio Corporation Information
6.13.2 Boya Bio Plasma Albumin Description and Business Overview
6.13.3 Boya Bio Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Boya Bio Plasma Albumin Product Portfolio
6.13.5 Boya Bio Recent Developments/Updates
6.14 Yuanda Shuyang
6.14.1 Yuanda Shuyang Corporation Information
6.14.2 Yuanda Shuyang Plasma Albumin Description and Business Overview
6.14.3 Yuanda Shuyang Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Yuanda Shuyang Plasma Albumin Product Portfolio
6.14.5 Yuanda Shuyang Recent Developments/Updates
6.15 Weiguang Bio
6.15.1 Weiguang Bio Corporation Information
6.15.2 Weiguang Bio Plasma Albumin Description and Business Overview
6.15.3 Weiguang Bio Plasma Albumin Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Weiguang Bio Plasma Albumin Product Portfolio
6.15.5 Weiguang Bio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Plasma Albumin Industry Chain Analysis
7.2 Plasma Albumin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Plasma Albumin Production Mode & Process
7.4 Plasma Albumin Sales and 麻豆原创ing
7.4.1 Plasma Albumin Sales Channels
7.4.2 Plasma Albumin Distributors
7.5 Plasma Albumin Customers
8 Plasma Albumin 麻豆原创 Dynamics
8.1 Plasma Albumin Industry Trends
8.2 Plasma Albumin 麻豆原创 Drivers
8.3 Plasma Albumin 麻豆原创 Challenges
8.4 Plasma Albumin 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Grifols
CSL
Takeda
Octapharma
CBPO
Hualan Bio
Kedrion
Shanghai RAAS
LFB Group
Biotest
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.